Legal & RegulatoryEvent: September 7, 2026
Kiin Bio broke down how Merck spent USD 1 billion developing a subcutaneous Keytruda and why the next patent cliff won't break down.
Published
Signal category
Legal & Regulatory
Quote
“Merck have spent USD 1 billion developing a subcutaneous Keytruda.”
— Kiin Bio team
Company
Kiin Bio
Innovate Health
- Industry
- Biotechnology Research
- Location
- London, GB
- Company size
- 10 employees
Our mission is to bridge AI and Life Sciences. The next breakthrough in drug discovery is a team of Virtual Scientists that designs, runs and interprets complex experiments by intelligently using the right software and data. Kiin Bio is bringing this vision to life with KiinOS. Follow us and subscribe to our newsletter (https://newsletter.kiin.bio/) for actionable intelligence, strategic insights, and unparalleled expertise in AI-driven solutions for the life science sector!
Founded 2024